/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA).
- Focuses on digitizing cell manufacturing processes through robotics technology
TOKYO, May 21, 2024 /PRNewswire/ Astellas Pharma Inc. today announced that it signed a memorandum of.
- Focuses on digitizing cell manufacturing processes through robotics technology TOKYO, May 21, 2024 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced
/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a.